throbber
HHS Public Access
`Author manuscript
`Cytokine Growth Factor Rev. Author manuscript; available in PMC 2019 June 01.
`Published in final edited form as:
`Cytokine Growth Factor Rev. 2018 June ; 41: 10–17. doi:10.1016/j.cytogfr.2018.04.004.
`IL-6 Family Cytokines: Key inflammatory mediators as
`biomarkers and potential therapeutic targets
`Nese Unver1,* and Florencia McAllister1
`1Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center,
`Houston, TX 77030, USA
`Abstract
`IL-6 is a critical cytokine in acute phase response and involved in the pathogenesis of several
`chronic inflammatory diseases including cancer. Studies have highlighted that levels of IL-6 and
`its family members can be useful for diagnosis, prognosis of relapse-free survival and recurrence.
`IL-6 family cytokines have been identified as cancer biomarkers through screening of
`inflammatory mediators in different fluids including saliva, serum, and bronchoalveolar lavage
`fluid (BALF). IL-6 can be modulated by chemopreventive drugs, small molecules, monoclonal
`antibodies and immune checkpoint inhibitors. Unveiling the different sources of IL-6, the
`interaction between IL-6 and its cellular targets, the IL-6-dependent tumor resistance mechanisms,
`and the identification of novel regulators of IL-6 are some of the highly complex topics included in
`this review and their understanding could aid cancer biomarkers and therapy development.
`Graphical abstract
`
`Author Manuscript
`
`Author Manuscript
`
`Author Manuscript
`
`Author Manuscript
`
`*Corresponding author at: Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston,
`TX 77030, USA, nunver@mdanderson.org (Nese Unver).
`Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
`customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
`the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
`discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
`Conflicts of interest statement
`None.
`
`Lassen - Exhibit 1028, p. 1
`
`

`

`Page 2
`Unver and McAllister
`Keywords
`IL-6; IL-6 family; cytokine; cancer biomarker; immunoprevention
`1. IntroductionInflammation, one of the hallmarks of cancer, is a known contributor to cancer initiation and
`progression [1]. The role of IL-6 in the development and progression of inflammation-
`associated cancers has been widely described. Several cells in the tumor microenvironment
`are capable of secreting IL-6, including epithelial oncogenic cells as well as stromal cells
`including immune cells [2]. Besides its direct effect on tumor cell proliferation, IL-6 is also
`a major immunomodulatory agent, playing active roles in the regulation of acute phase
`reactions, activation of T helper cells, inhibition of T regulatory (Tregs) cells and
`differentiation of B cells by orchestrating innate and adaptive immune responses [3]. Dual
`roles for IL-6 have been described in some specific tumors as it is the example of lung
`cancer in which IL-6 has a preventive role in the tumor initiation but it is also capable of
`enhancing cancer progression [4] [5].
`IL-6 monoclonal antibody (Siltuximab) has been tested in mouse xenografts models of lung
`cancer and it has tumor inhibitory effect particularly potent when cancer-associated
`fibroblasts were coadministered, suggesting that IL-6 secreted by the stroma might be more
`susceptible to the antibody effect [6]. Cancer associated fibroblasts (CAF) in hepatocellular
`carcinoma (HCC) also secrete high levels of IL-6 which contributes to tumor progression via
`recruitment of immune cells with immunosuppressive phenotype. This data suggests that
`IL-6 blockade in addition to immune checkpoint inhibitors may potentially overcome the
`immune-checkpoint inhibitor resistance in some types of cancer [7]. The gp130 f/f (IL6st)
`knock-in mouse model exhibits hyper activation of the STAT3 arm of IL6. When this
`transgenic mouse is crossed with Kras(G12D) mice to study lung tumorigenesis, an increase
`in atypical adenomatous hyperplasia, adenocarcinoma in situ, and invasive adenocarcinoma
`throughout the lung are observed, suggesting that IL-6 trans-signaling can be a target for the
`treatment of KRAS-driven lung adenocarcinoma [8].
`2. Identification of IL-6 family cytokines as cancer biomarkers
`2.1. IL-6
`The IL-6-type family cytokines are IL-6, IL-11, IL-31, Cardiotrophin-1, Ciliary neurotrophic
`factor (CNTF), Cardiotrophin-like cytokine (CLC), Granulocyte-colony stimulating factor
`(G-CSF), Leptin, Leukemia inhibitory factor (LIF), Neuropoietin and Oncostatin M. The
`main cellular source of IL-6 is monocytes and T cells but it can also be produced by other
`cells including epithelial cells [9]. IL-6 promotes Th17 cells development when combined
`with TGF-(cid:868)(cid:3)[10], inhibits TGF-(cid:868)-induced Treg differentiation [11], plays a role in
`neutrophil and macrophage recruitment and is also associated with the pathogenesis of
`chronic inflammatory disease [12]. IL-6 activates STAT3 through two pathways: classical
`and trans-signaling. Classical signaling of IL-6 occurs in cells expressing IL-6R(cid:867) and it
`induces anti-inflammatory molecules [12]. On the other hand, trans-signaling is possible in
`Cytokine Growth Factor Rev. Author manuscript; available in PMC 2019 June 01.
`
`Author Manuscript
`
`Author Manuscript
`
`Author Manuscript
`
`Author Manuscript
`
`Lassen - Exhibit 1028, p. 2
`
`

`

`Unver and McAllister
`
`Page 3
`all cells expressing gp130 and causes pro-inflammatory cytokines induction which drives
`chronic inflammation. IL-6 not only contributes to cancer related inflammation but also
`plays crucial roles in DNA damage repair, anti-oxidant defense system, proliferation,
`invasion, metastasis, angiogenesis and metabolic remodeling [12] (Figure 1).
`Screening of cytokines can serve to identify immunological response-related soluble factors
`which may be increased in cancer even at early stages. A study that included 224
`hepatocellular carcinoma (HCC) cases and 644 controls revealed that higher serum levels of
`IL-6 are predictive of increased HCC risk, independently of hepatitis virus infection,
`radiation exposure and lifestyle-associated factors [13]. IL-6 can also be involved in
`stemness and metastasis via its downstream target, Osteopontin, in HCC. Plasma levels of
`IL-6 and Osteopontin were found to be independent prognostic factors for HCC patients
`[14].Serum levels of IL-6 have been associated with tumor progression. In bladder cancer, IL-6
`serum levels were found to be remarkably higher in patients with recurrence compared to
`non-recurrent patients [15]. In pancreatic ductal adenocarcinoma (PDAC), serum levels of
`IL-6 can be useful as diagnostic biomarker and this cytokine has also been implicated in the
`progression of this type of tumor [16]. It has also been reported as a useful classifier for the
`identification of high-risk stage I lung adenocarcinoma patients [17]. In addition to serum
`based studies of inflammatory mediators, tissue microarray and immunohistochemistry
`analysis of IL-6 in human cervical cancer tissues suggest its usefulness as prognostic
`biomarker as well as potential therapeutic targets for treatment of cervical cancer [18].
`Advanced or metastatic colorectal cancer patients with high serum IL-6 levels had poorer
`overall survival (OS), progression-free survival (PFS) and anti-VEGF resistance [19] than
`patients with lower levels. In addition to solid tumors, elevated serum levels of IL-6 can
`serve as a biomarker in hematological malignancies like Hodgkin’s lymphoma [20]. IL-6
`and the JAK-STAT3 signaling pathway have also been found upregulated in
`myeloproliferative neoplasms (MPN). Interestingly, the recent JAK1/2 inhibitor trials in
`MPNs demonstrated that lessening inflammation can be even more helpful that targeting
`mutations [21].
`Besides serum levels, Il-6 detection in saliva has been proposed as a useful diagnostic
`biomarker of cancers like oral squamous cell carcinoma (OSCC) [22]. In OSCC, IL-6
`modulates resistance to radiation by inhibiting oxidative stress through the Nrf2-antioxidant
`pathway [23].
`2.2. IL-6 as a critical inflammatory marker in murine models
`IL-6 is the most highly elevated cytokine in COPD-like inflammatory mouse model and is
`required for lung cancer promoted by COPD-like inflammation [24]. IL-6 differently
`modulates both tumor initiation and progression via activating STAT3 in a mouse model of
`lung cancer induced by the Kras oncogene. It suppresses lung cancer initiation via sustaining
`lung homeostasis, modulating lung macrophages and activating cytotoxic CD8+ T cells
`under Kras oncogenic stress, and on the other hand it promotes lung cancer cell growth by
`promoting the cell proliferation regulator Cyclin D1 [4]. In a different lung cancer mouse
`model, CcspCre/+ KrasLSL-G12D/+ (CC-LR), IL-6 and IL-6 class cytokine LIF were highly
`Cytokine Growth Factor Rev. Author manuscript; available in PMC 2019 June 01.
`
`Author Manuscript
`
`Author Manuscript
`
`Author Manuscript
`
`Author Manuscript
`
`Lassen - Exhibit 1028, p. 3
`
`

`

`Page 4
`detected in BALF from mice with tumors. Chemopreventive treatment of mice with myo-
`inositol diminished IL-6 and phospho-STAT3 signaling, a process likely mediated by tumor
`associated macrophages [25].
`In the pancreas, KrasG12D activation induces premalignant lesions called pancreatic
`intraepithelial neoplasias (PanINs). IL-6 trans-signaling-dependent activation of Stat3/Socs3
`is required to promote murine PanIN progression to PDAC [26]. In a similar fashion, IL-6
`has been described as a critical tumor booster during early colitis-associated cancer (CAC).
`Its production by myeloid cells in the lamina propia has a protective role on normal and
`premalignant intestinal epithelial cells (IECs) against apoptosis [27].
`IL-6 has also been found increased during the development and malignant progression of
`astrocytomas [28]. Although suppression of IL-6 does not influence preneoplastic
`astrogliosis, it prevents tumor formation in a spontaneous GFAP-v-src+/− mouse astrocytoma
`model. In a murine model of osteosarcoma, tumor progression and recurrence are modulated
`by IL-6 via promoting tumor self-seeding by CTCs [29].
`In murine models of hematological malignancies such as CML, increased IL-6 levels were
`detected in BCR/ABL transgenic mice. IL-6 produced by myeloid CML cells inhibits
`lymphoid differentiation from multipotent progenitor cells [30] and shapes the CML
`pathogenesis.
`Apart from tumor cells derived IL-6 secretion, mesenchymal stem cells (OvMSC) can
`secrete IL-6 which contributes to tumor progression in models like ovarian cancer.
`Coinjection of OvMSC with ovarian cancer cells enhances ovarian tumor development in
`NOD-SCID mice [31]. In a murine model of hepatocellular carcinoma (HCC), IL-6 is
`predominantly expressed by CAFs creating an immunosuppressive environment via up-
`regulation of inhibitory immune checkpoints [7] (Figure 2).
`A study of gastric tumorigenesis in mice challenged with N-methyl-N-nitrosourea
`demonstrated the importance of IL-6 in driving tumor development through STAT3
`stimulation by using IL-6 knockout mice [32]. Inoculation of another chemical carcinogen,
`diethylnitrosamine (DEN), remarkably increased serum interleukin-6 (IL-6) concentration in
`males compared to females. Estrogen-mediated suppression of IL-6 production by Kupffer
`cells diminished liver cancer risk in females in the DEN-induced hepatocellular carcinoma
`mouse model [33], suggesting that suppression of IL-6 abrogates the gender differences in
`hepatic carcinogenesis.
`IL-11 was identified as a 19 kDa soluble factor belonging to the IL-6 cytokine family in the
`supernatant of bone-marrow derived stromal cell. The main cellular source of IL-11 are
`bone, connective tissue, and malignant cells [34]. Through transmembrane protein
`glycoprotein-130 beta subunit, IL-11 shows pro-tumorigenic activities such as proliferation,
`self-renewal, invasion and angiogenesis [34]. In a prospective cohort of 60 smokers
`including patients with lung cancer, COPD and both, IL-11 was found to be a specific
`biomarker for the diagnosis of lung adenocarcinoma in BALF specimens [35].
`Cytokine Growth Factor Rev. Author manuscript; available in PMC 2019 June 01.
`
`Unver and McAllister
`
`Author Manuscript
`
`Author Manuscript
`
`Author Manuscript
`
`2.3. IL-11
`
`Author Manuscript
`
`Lassen - Exhibit 1028, p. 4
`
`

`

`Page 5
`Although there is a limitation with cohort size and short follow-up time, IL-11 has been
`found to be a useful biomarker for diagnosis and prognosis in patients with pancreatic
`cancer [36]. Assessment of IL-11 expression by immunohistochemistry in clear-cell RCC
`(ccRCC) has demonstrated its association with increased risk of recurrence and poor
`survival for ccRCC patients with early-stage disease. As a result of immunohistochemical
`evaluation of tissue microarrays including paired tumor/peritumoral liver tissue from 290
`patients who had undergone hepatectomy for histologically proven HCC, intra-tumoral
`IL-11 is significantly concordant with higher tumor node metastasis (TNM) stage and has
`been found to be an independent prognostic factor for progression-free survival (PFS) [37],
`[38].
`2.4. Oncostatin MOncostatin M (OSM) is produced by monocytes, macrophages, T cells, neutrophils and
`dendritic cells. Oncostatin M plays fundamental roles in heart remodeling, inflammation,
`hematopoiesis, liver regeneration and cancer [39]. OSM levels are associated with
`inflammatory response-genes, epidermal growth factor (EGF) signaling and epithelial-to-
`mesenchymal transition (EMT) in human estrogen receptor (ER)-negative/human epidermal
`growth factor receptor 2 (HER2)-negative breast cancer [40]. High expression of OSM and
`OSM receptor (OSMR) mRNA have been associated with reduced ER and progesterone
`receptor (PR) protein levels in a cohort of 70 invasive breast cancers [41]. OSM stimulates
`the expression of ZEB1, Snail (SNAI1), and OSMR as well as the CSC phenotypes in
`pancreatic cancer, suggesting that therapeutic targeting of the OSM/OSMR axis could be
`useful for patients with PDAC [42]. Analysis of serum diagnostic biomarkers in PDAC
`showed that OSM was overexpressed in PDAC patients versus controls (AUC=0.744). OSM
`could also be a predictive biomarker for treatment of PDAC response to drugs like
`gemcitabine and erlotinib [43].
`IL-31 is mainly expressed by circulating Th2 lymphocytes and skin-homing CLA+ CD45RO
`+ T cells. IL-31 binds its heterodimeric receptor formed from IL-31RA and the OSMR
`chains and this leads to phosphorylation of Jak1/2, which in turn, triggers phosphorylation of
`STAT1/3/5 or PI3K/AKT. These pathways promote skin inflammation, development of T
`cell type-2 inflammation in asthma and allergic rhinitis as well as gut inflammation.
`Elevated serum levels of IL-31 contribute to the pathogenesis of different tumor types
`including endometrial, lung cancer, cutaneous T cell lymphoma, follicular B cell lymphoma
`[44] [45]. Expression of IL-31 was found to be increased in patients with mastocytosis
`compared with those seen in healthy control subjects (P < .0473) [46].
`3. Identification of IL-6 family cytokines as potential cancer treatment target
`3.1. IL-6
`Activation of IL-6/STAT3 pathway has been reported in various cancer types. Blockade of
`IL-6/STAT3 has been targeted by potent chemopreventive drugs. As an example, disulfiram,
`targets cancer stem cells [47] and STAT3 signaling in triple-negative breast cancer [48].
`Targeting STAT3 could cause elimination of cancer stem-like cells and contribute to
`Cytokine Growth Factor Rev. Author manuscript; available in PMC 2019 June 01.
`
`2.5. IL-31
`
`Author Manuscript
`
`Author Manuscript
`
`Unver and McAllister
`
`Author Manuscript
`
`Author Manuscript
`
`Lassen - Exhibit 1028, p. 5
`
`

`

`3.2. IL-11
`
`Page 6
`blockade of recurrence in breast cancer. Recently published papers have also focused on
`small molecules such as Tanshinone IIA (Tan-IIA) possessing anti-cancer and anti-
`inflammatory activities or proteins like repebody which binds IL-6 ligand with high affinity
`attenuating STAT3 signaling and inhibiting human breast cancer stem cells growth and
`NSCLC, respectively [49] [50]. In prostate cancer, elevation of IL-6 and loss of ESE3/EHF,
`required for differentiation of human prostate epithelial cells, were associated with STAT3
`activation. IL-6 upregulates cancer stem-like and metastatic spread-related gene expressions,
`indicating that identification of the novel regulator sites in IL-6 promoter could be beneficial
`for prostate cancer with loss of ESE3/EHF. Besides transcriptional modifiers, a long non-
`coding RNA identified as antisense IL6 stimulates IL-6 expression, which induces IL-6/
`STAT3 activation and increases invasive ability of glioblastoma cells [51].
`Interleukin-6 (IL-6) is a growth factor for estrogen receptor-(cid:867)(cid:3)(ER(cid:867))-positive breast cancer.
`Preclinical models have shown that breast cancer patients-derived xenografts respond to IL-6
`blocking antibody [52]. Siltuximab has been well tolerated in patients with solid tumors
`including ovarian and KRAS-mutant cancers [53]. Siltuximab inhibits the growth of human
`renal cell carcinoma (RCC) in nude mice and remarkably stabilizes disease in patients with
`progressive metastatic RCC [54]. Since IL-6 has been involved in resistance to anti-
`angiogenic treatment, combinational therapy targeting angiogenic factors could be useful to
`prevent or minimize side effects of the monoclonal antibody.
`IL-11 is the dominant IL-6 family cytokine identified as an inducer of oncogenic STAT3
`activity in the gastrointestinal (GI) epithelium during tumorigenesis, which can be targeted
`pharmacologically. mIL-11 Mutein treatment remarkably diminished overall tumor burden,
`gastric epithelial hyperplasia and reduced expression of the inflammatory mediators in the
`gastrointestinal tumorigesis model [55]. IL-11/IL-11R(cid:867) axis modulates human
`osteosarcoma through STAT3 [56–58]. Bone metastasis-targeting peptidomimetic
`(BMTP-11) directed against IL-11R(cid:867) retards primary tumor growth and lung metastasis in
`preclinical models of human osteosarcoma. BMTP-11 in combination with gemcitabine
`shows better outcomes than BMTP-11 alone [59]. Similarly, targeting IL-11R(cid:867) in
`combination with doxorubicin therapeutically improves the effect of chemotherapy in high
`grade Type I endometrioid cancer [60].
`3.3. Oncostatin MThe role of Oncostatin M on tumor progression is controversial. A lung cancer study has
`shown that Oncostatin M inhibits metastasis of lung adenocarcinoma by suppressing SLUG
`expression via STAT1/STAT3 dependent signaling [61].
`Oncostatin M (OSM) was described as a robust inducer of mesenchymal/CSC. Eradication
`of OSM or suppression of STAT3 or SMAD3 causes a significant reversion to a non-
`invasive, epithelial phenotype [62]. OSMR has been described as an inducer of
`mesenchymal properties in glioblastoma. Analysis of TCGA data has showed that OSMR
`but not IL-6R or LIFR is upregulated in GBM [63]. In contrast to osteosarcomas and
`chondrosarcomas, OSM induces proliferation of Ewing carcinoma cells which are rare bone
`Cytokine Growth Factor Rev. Author manuscript; available in PMC 2019 June 01.
`
`Unver and McAllister
`
`Author Manuscript
`
`Author Manuscript
`
`Author Manuscript
`
`Author Manuscript
`
`Lassen - Exhibit 1028, p. 6
`
`

`

`Page 7
`Unver and McAllister
`malignant cells, suggesting its potential utility for therapeutic intervention [64]. In sum,
`OSM/OSMR could be potential cancer therapeutic targets besides their usefulness as
`diagnostic biomarkers [63].
`4. Promising Trials targeting IL-6/ IL-6R and IL-11/IL-11R(cid:867) in cancer
`Inhibition of IL-6 and IL-6R using specific monoclonal antibodies is being tested
`therapeutically for many different types of cancer [65]. Phase I and II studies assessed
`siltuximab in various solid tumors including ovarian, pancreatic, colorectal, head & neck and
`lung neoplasms [66]. In addition to solid tumors, siltuximab has also been evaluated for
`patients with multiple myeloma who are relapsed or refractory [67]. Phase I trials related to
`siltuximab are also undergoing in hematological tumors including non-Hodgkin’s
`lymphomas (NHL) and B cell Chronic Lymphocytic Leukemia [68]. In pancreatic cancer, a
`current phase II trial will evaluate the safety and efficacy of gemcitabine and nab-paclitaxel
`with or without tocilizumab (monoclonal antibody against IL-6 receptor) (Clinical trial
`identification: NCT02767557). IL-6R has been described as an independent prognostic
`factor and potential therapeutic target for ovarian cancer. Tocilizumab has been found to be
`well tolerated in clinical trials [69]. The on-going phase I trial will evaluate tolerability and
`safety of tocilizumab given with trastuzumab and pertuzumab in subject with metastatic
`HER2+ breast cancer (Clinical trial identification: NCT03135171).
`Recombinant IL-11 (Neumega) is also under clinical development for acceleration of
`platelet recovery and inhibition of inflammation in cancer patients to prevent chemotherapy-
`induced thrombocytopenia [70]. BMTP-1 for IL-11R(cid:867) has been shown as a promising drug
`candidate in metastatic prostate cancer [71]. A comprehensive list with the completed and
`ongoing clinical trials targeting IL-6 family cytokines as well as their receptors can be found
`in Table 1.
`5. IL-6/STAT3 pathway can be targeted for cancer prevention
`Chemoprevention targets many steps including tumor initiation, promotion and progression.
`Dietary derived products play a role in all steps of the carcinogenic process [72].
`Administration of (cid:867)-Tocopherol (vitamin E) in an inducible mouse model of non-Hodgkin's
`T-cell lymphoma diminishes IL-6 gene and protein expression [73]. In a similar manner,
`plant derived glycoprotein (UDN glycoprotein) inhibits the levels of IL-6 in 1,2-
`dimethylhydrazine-treated mice, suggesting that UDN glycoprotein may be an effective
`agent for colon cancer prevention [74]. Intragastric treatment with Isoliquiritigenin,
`originated from licorice root, downregulates IL-6 signaling in a chemically induced mouse
`model of colon carcinogenesis and it suppresses macrophage polarization into M2-like
`phenotype partially through IL-6/STAT3 pathway [75]. IL-6/STAT3 pathway can be also
`regulated by balsalazide (a 5-ASA prodrug) and probiotic agent VSL#3 in colorectal cancer
`chemoprevention [76]. The diet-derived polyphenols Apigenin and luteolin have an
`inhibitory effect on angiogenesis mediated by IL-6/STAT3 pathway in human endothelial
`cells [77]. Another example of IL-6 suppression is the mechanism of Quercetin, a compound
`found in many plant-based foods, which has been proposed for chemoprevention and
`treatment of glioblastoma [78]. Finally, the estrogen receptor modulator Evista (Raloxifene
`Cytokine Growth Factor Rev. Author manuscript; available in PMC 2019 June 01.
`
`Author Manuscript
`
`Author Manuscript
`
`Author Manuscript
`
`Author Manuscript
`
`Lassen - Exhibit 1028, p. 7
`
`

`

`Page 8
`Unver and McAllister
`HCl), found to also inhibit IL-6/GP130 protein interaction, represents a promising
`chemopreventive agent for breast, colon, multiple myeloma and liver cancer [79] [80].
`6. Conclusion & Perspectives
`IL-6 is a multi-functional cytokine and its abnormal expression levels are associated with
`cancer diagnosis, prognosis and disease progression. Recently, the new area of
`immunoprevention has gained major attention. Direct targeting of the IL-6 family members
`with some of the monoclonal antibodies currently described in clinical trials for treatment of
`various cancers could potentially be used for cancer prevention [81] [82].
`Development of monoclonal antibodies and small molecules in addition to defining de novo
`transcriptional regulators targeting trans-signaling of IL-6 would improve cancer therapeutic
`strategies. Defining the origin of IL-6 and IL-6 family cytokines in the tumor
`microenvironment and molecular stratification of cancer subtypes based on these key
`inflammatory mediators would open up novel insights for chemoresistance and
`immunotherapy in cancer therapy. Using in vivo models, application of combinational
`therapies including IL-6 blockade and conventional chemotherapeutic or immunotherapy
`drugs will provide basis for clinical research.
`Acknowledgments
`Dr. McAllister received support from the PanCAN/AACR Career Development Award (14-20-25 MCAL), National
`Pancreas Foundation and V Foundation (V Scholar). Dr McAllister is also a Paul Calabresi K12 clinical scholar
`(NCI grant awarded to MDACC K12CA088084-16A1).
`AbbreviationsBALF
`Bronchoalveolar lavage fluid
`Colitis-associated cancer
`CAC
`Cancer associated fibroblast
`CAF
`Clear cell renal cell carcinoma
`ccRCC
`Cardiotrophin-like cytokine
`CLC
`Chronic myeloid leukemia
`CML
`Ciliary neurotrophic factor
`CNTF
`Chronic obstructive pulmonary disease
`COPD
`Circulating tumor cells
`CTC
`Epidermal Growth Factor
`EGF
`Epithelial–mesenchymal transition
`EMT
`Granulocyte-colony stimulating factor
`GCSF
`Cytokine Growth Factor Rev. Author manuscript; available in PMC 2019 June 01.
`
`Author Manuscript
`
`Author Manuscript
`
`Author Manuscript
`
`Author Manuscript
`
`Lassen - Exhibit 1028, p. 8
`
`

`

`Unver and McAllister
`
`Page 9
`
`Glycoprotein 130
`Gp130
`Hepatocellular carcinoma
`HCC
`Intestinal epithelial cells
`IEC
`Interleukin 11
`IL-11
`Interleukin 31
`IL-31
`Interleukin 6
`IL-6
`Interleukin 6 receptor
`IL-6R
`Januse kinase 1/2
`Jak1/2
`Leukemia inhibitory factor
`LIF
`Leukemia inhibitory factor receptor
`LIFR
`Mitogen-activated protein kinase
`MAPK
`Myeloproliferative neoplasms
`MPN
`Nuclear factor (erythroid-derived 2)-like 2
`Nrf-2
`Non-Hodgkin’s lymphomas
`NHL
`Non-small cell lung cancer
`NSCLC
`Oral squamous cell carcinoma
`OSCC
`Pancreatic intraepithelial neoplasia
`PanIN
`Pancreatic ductal adenocarcinoma
`PDAC
`Progression-free survival
`PFS
`PI3K/AKTThe phosphatidylinositol-3-kinase/Protein kinase B
`Renal cell carcinoma
`RCC
`Signal transducer and activator of transcription 1
`STAT1
`Signal transducer and activator of transcription 3
`STAT3
`Tumor node metastasis
`TNM
`Regulatory T cell
`Treg
`References1. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh
`hallmark of cancer: links to genetic instability. Carcinogenesis. 2009; 30(7):1073–81. [PubMed:
`19468060]
`2. Fisher DT, Appenheimer MM, Evans SS. The two faces of IL-6 in the tumor microenvironment.
`Semin Immunol. 2014; 26(1):38–47. [PubMed: 24602448]
`Cytokine Growth Factor Rev. Author manuscript; available in PMC 2019 June 01.
`
`Author Manuscript
`
`Author Manuscript
`
`Author Manuscript
`
`Author Manuscript
`
`Lassen - Exhibit 1028, p. 9
`
`

`

`Page 10
`3. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of
`the cytokine interleukin-6. Biochim Biophys Acta. 2011; 1813(5):878–88. [PubMed: 21296109]
`4. Qu Z, Sun F, Zhou J, Li L, Shapiro SD, Xiao G. Interleukin-6 Prevents the Initiation but Enhances
`the Progression of Lung Cancer. Cancer Res. 2015; 75(16):3209–15. [PubMed: 26122841]
`5. Rath T, Billmeier U, Waldner MJ, Atreya R, Neurath MF. From physiology to disease and targeted
`therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Arch Toxicol.
`2015; 89(4):541–54. [PubMed: 25632846]
`6. Song L, Smith MA, Doshi P, Sasser K, Fulp W, Altiok S, Haura EB. Antitumor efficacy of the anti-
`interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer. J Thorac Oncol.
`2014; 9(7):974–82. [PubMed: 24922005]
`7. Liu H, Shen J, Lu K. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma
`cancer development in mouse model. Biochem Biophys Res Commun. 2017; 486(2):239–244.
`[PubMed: 28254435]
`8. Brooks GD, McLeod L, Alhayyani S, Miller A, Russell PA, Ferlin W, Rose-John S, Ruwanpura S,
`Jenkins BJ. IL6 Trans-signaling Promotes KRAS-Driven Lung Carcinogenesis. Cancer Res. 2016;
`76(4):866–76. [PubMed: 26744530]
`9. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J
`Cancer. 2005; 41(16):2502–12. [PubMed: 16199153]
`10. Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol. 2010; 40(7):1830–
`5. [PubMed: 20583029]
`11. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl
`SM, Schoeb TR, Weaver CT. Transforming growth factor-beta induces development of the T(H)17
`lineage. Nature. 2006; 441(7090):231–4. [PubMed: 16648837]
`12. Kumari N, Dwarakanath BS, Das A, Bhatt AN. Role of interleukin-6 in cancer progression and
`therapeutic resistance. Tumour Biol. 2016; 37(9):11553–11572. [PubMed: 27260630]
`13. Ohishi W, Cologne JB, Fujiwara S, Suzuki G, Hayashi T, Niwa Y, Akahoshi M, Ueda K, Tsuge M,
`Chayama K. Serum interleukin-6 associated with hepatocellular carcinoma risk: a nested case-
`control study. Int J Cancer. 2014; 134(1):154–63. [PubMed: 23784949]
`14. Wang CQ, Sun HT, Gao XM, Ren N, Sheng YY, Wang Z, Zheng Y, Wei JW, Zhang KL, Yu XX,
`Zhu Y, Luo Q, Yang LY, Dong QZ, Qin LX. Interleukin-6 enhances cancer stemness and promotes
`metastasis of hepatocellular carcinoma via up-regulating osteopontin expression. Am J Cancer
`Res. 2016; 6(9):1873–1889. [PubMed: 27725896]
`15. Kumari N, Agrawal U, Mishra AK, Kumar A, Vasudeva P, Mohanty NK, Saxena S. Predictive role
`of serum and urinary cytokines in invasion and recurrence of bladder cancer. Tumour Biol. 2017;
`39(4) 1010428317697552.
`16. Kim HW, Lee JC, Paik KH, Kang J, Kim J, Hwang JH. Serum interleukin-6 is associated with
`pancreatic ductal adenocarcinoma progression pattern. Medicine (Baltimore). 2017; 96(5):e5926.
`[PubMed: 28151872]
`17. Meaney CL, Zingone A, Brown D, Yu Y, Cao L, Ryan BM. Identification of serum inflammatory
`markers as classifiers of lung cancer mortality for stage I adenocarcinoma. Oncotarget. 2017
`18. Song Z, Lin Y, Ye X, Feng C, Lu Y, Yang G, Dong C. Expression of IL-1alpha and IL-6 is
`Associated with Progression and Prognosis of Human Cervical Cancer. Med Sci Monit. 2016;
`22:4475–4481. [PubMed: 27866212]
`19. Hara M, Nagasaki T, Shiga K, Takahashi H, Takeyama H. High serum levels of interleukin-6 in
`patients with advanced or metastatic colorectal cancer: the effect on the outcome and the response
`to chemotherapy plus bevacizumab. Surg Today. 2017; 47(4):483–489. [PubMed: 27549777]
`20. Levin LI, Breen EC, Birmann BM, Batista JL, Magpantay LI, Li Y, Ambinder RF, Mueller NE,
`Martinez-Maza O. Elevated serum levels of sCD30 and IL-6 and detectable IL-10 precede
`classical Hodgkin lymphoma diagnosis. Cancer Epidemiol Biomarkers Prev. 2017
`21. Cokic VP, Mitrovic-Ajtic O, Beleslin-Cokic BB, Markovic D, Buac M, Diklic M, Kraguljac-
`Kurtovic N, Damjanovic S, Milenkovic P, Gotic M, Raj PK. Proinflammatory Cytokine IL-6 and
`JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms. Mediators Inflamm. 2015;
`2015:453020. [PubMed: 26491227]
`Cytokine Growth Factor Rev. Author manuscript; available in PMC 2019 June 01.
`
`Unver and McAllister
`
`Author Manuscript
`
`Author Manuscript
`
`Author Manuscript
`
`Author Manuscript
`
`Lassen - Exhibit 1028, p. 10
`
`

`

`Page 11
`22. Sahibzada HA, Khurshid Z, Khan RS, Naseem M, Siddique KM, Mali M, Zafar MS. Salivary IL-8,
`IL-6 and TNF-alpha as Potential Diagnostic Biomarkers for Oral Cancer. Diagnostics (Basel).
`2017; 7(2)
`23. Matsuoka Y, Nakayama H, Yoshida R, Hirosue A, Nagata M, Tanaka T, Kawahara K, Sakata J,
`Arita H, Nakashima H, Shinriki S, Fukuma D, Ogi H, Hiraki A, Shinohara M, Toya R, Murakami
`R. IL-6 controls resistance to radiation by suppressing oxidative stress via the Nrf2-antioxidant
`pathway in oral squamous cell carcinoma. Br J Cancer. 2016; 115(10):1234–1244. [PubMed:
`27736845]
`24. Ochoa CE, Mirabolfathinejad SG, Ruiz VA, Evans SE, Gagea M, Evans CM, Dickey BF,
`Moghaddam SJ. Interleukin 6, but not T helper 2 cytokines, promotes lung carcinogenesis. Cancer
`Prev Res (Phila). 2011; 4(1):51–64. [PubMed: 21098042]
`25. Unver N, Delgado O, Zeleke K, Cumpian A, Tang X, Caetano MS, Wang H, Katayama H, Yu H,
`Szabo E, Wistuba, Moghaddam SJ, Hanash SM, Ostrin EJ. Reduced IL-6 levels and tumor-
`associated phospho-STAT3 are associated with reduced tumor development in a mouse model of
`lung cancer chemoprevention with myo-inositol. Int J Cancer. 2018; 142(7):1405–1417. [PubMed:
`29134640]
`26. Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Kloppel G, Yoshimur

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket